Calypte Biomedical Corp (fka CYPT)

[scion]

Marr Private Placements
-----------------------
PIPE at $0.30 per share
Marr Technologies B.V (9) $0.30 per $2,500 $2,300 8/1/03 $0.152 8,333.3
share

PIPE at $0.50 per share
Marr Technologies B.V (9) $0.50 per $10,000 $9,600 9/1/03 $0.820 20,000.0
share ------- ------ --------
Total Marr Private Placements $12,500 $11,900 28,333.3
======= ======= ========

---------------------
(1) The Bristol Debentures and Warrants, the 8% Convertible Notes, the
Other Restart Financings, the Mercator 12% and 10% Debentures and warrants and
the Marr Technologies B.V. PIPE's were issued under exemptions provided by
Regulation S. The Company could issue no shares under the equity line with
Townsbury until it had completed an effective registration for the underlying
shares. With the exception of Marr Technologies B.V., which is an affiliate of
the Company based on its August and September 2003 investments, none of the
entities listed above is or has been an affiliate of the Company. Other than
Marr Technologies B.V., all of the listed investors were subject to ownership
limitations restricting their ownership of the Company's stock to a maximum of
4.9% or 9.9%, depending on the specific agreement.

....the Company issued 12%
convertible debentures of $250,000 each to Alpha Capital AG, Gamma Opportunity
Capital Partners, LP and Goldplate Investment Partners, assignees under the MMF
$2 million commitment agreement mentioned above covering these two commitments.
The Company had prepaid $75,000 in fees and received gross proceeds of $750,000.
A portion of the proceeds were used to repay a $400,000 MMF advance from June 6,
2003, along with a fee of $12,000.

CALYPTE BIOMEDICAL CORP filed this 10QSB on 11/14/2003.

http://www.10kwizard.com/filing.php?param=repo%3Dtenk-exp%3D...